6/28/23, 9:56 PM EMPEROR-Reduced Pathway Feedback Search Clinical Topics Home Studies EMPEROR Reduced EMPEROR Reduced Disease Heart failure Trial question What is the role of empagliflozin in patients with HF? Study design Multi-center Double blinded RCT Population Characteristics of study participants 24.0% female N = 3730 76.0% male 3730 patients (893 female, 2837 male) Inclusion criteria: adult patients with chronic HF and an ejection fraction 40% who were receiving recommended therapy Key exclusion criteria: myocardial infarction, major cardiovascular surgery or stroke in the past 90 days; heart transplant recipient; acute decompensated HF; symptomatic hypotension; indication of liver disease; impaired renal function Interventions N=1863 empagliflozin (at a dose of 10 mg once daily) N=1867 placebo (matching placebo) Primary outcome Cardiovascular death or hospitalization for worsening heart failure 24.7 24.7 % 19 4 https://web.pathway.md/studies/rec4wn5P1oc265qiW 1/2 6/28/23, 9:56 PM EMPEROR-Reduced Pathway 19.4 18.5 % 12.3 % Significant decrease 6.2 % NNT = 19 0.0 % Empagliflozin Placebo Significant decrease in cardiovascular death or hospitalization for worsening HF (19.4% vs. 24.7%; HR 0.75, 95% CI 0.65 to 0.86) Secondary outcomes Significant decrease in total hospitalizations for HF (388 events vs. 553 events; HR 0.7, 95% CI 0.58 to 0.85) Significant decrease in the incidence of eGFR decline (0.55 mL/min/1.73 m /year vs. 2.28 mL/min/1.73 m /year; AD -1.73 mL/min/1.73 m /year, 95% CI -1.1 to -2.37) No significant difference in death from any cause (13.4% vs. 14.2%; HR 0.92, 95% CI 0.77 to 1.1) Safety outcomes No significant difference in adverse effects. Significant difference in serious renal outcome (1.6% vs. 3.1%). Conclusion In adult patients with chronic HF and an ejection fraction 40% who were receiving recommended therapy, empagliflozin was superior to placebo with respect to cardiovascular death or hospitalization for worsening HF. Reference Milton Packer, Stefan D Anker, Javed Butler et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. Open reference URL https://web.pathway.md/studies/rec4wn5P1oc265qiW 2/2